Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.

Support the Forward

Funded by readers like you DonateSubscribe
Breaking News

British Plan Takes Aim at ‘Jewish’ Cancer Gene With DNA Analysis

Britain launched a research programme on Monday that should eventually allow all cancer patients to have access to the kind of genetic analysis that led Hollywood star Angelina Jolie to decide to undergo a double mastectomy.

The project, involving the Institute of Cancer Research (ICR) in London, the U.S. gene sequencing firm Illumina , geneticists and cancer doctors, aims to find a way to allow more cancer genes be tested in more people.

Researchers announcing the 2.7 million pound ($4 million) project, funded by the Wellcome Trust medical charity, stressed this was not a response to reports last week of Jolie’s decision to undergo surgery to reduce her breast cancer risk.

“What we’re trying to do here is develop processes that will allow comprehensive and systematic use of genetic information in cancer medicine so that (more people) will be able to benefit from the types of information and situations we were hearing about last week (with the Jolie story),” said Nazneen Rahman, head of genetics at the ICR and a leader on the new project.

Mutations in some genes, known as cancer predisposition genes, greatly increase the risk that a person will get cancer.

Jolie tested positive for a high risk gene mutation that made her about five times more likely to develop breast cancer than women who do not carry this mutation, according to the U.S. National Cancer Institute.

There are nearly 100 other known cancer predisposition genes, but in Britain – where most healthcare is part of the taxpayer-funded National Health Service – testing for them is currently very restricted.

Yet recent advances in reading the genetic code, known as gene sequencing, mean that looking for gene mutations is now faster and cheaper than ever – paving the way for gene testing eventually to become routine for all cancer patients.

“It is very important to know if a mutation in a person’s genetic blueprint has caused their cancer,” Rahman told reporters at a briefing in London.

“It allows more personalised treatment, so for example such people are often at risk of getting another cancer and may choose to have more comprehensive surgery, or may need different medicines, or extra monitoring.”

The programme, called Mainstreaming Cancer Genetics, will use a new Illumina test called TruSight that can analyse 97 cancer predisposition genes within a few weeks for a few hundred pounds, Rahman said.

The new model will be piloted initially in women with breast or ovarian cancer at London’s Royal Marsden hospital, but the team hopes it will in future be used across the country and in many more types of cancer.

Engage

  • Events

    Haart to Haart

    Virtual

    Dec 7, 2022

    7 pm ET · 

    A conversation with Julia Haart and her son Shlomo, stars of Netflix's 'My Unorthodox Life,' about the new season and much more.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.